Skip to main content
. 2010 Mar;2(3):98–110. doi: 10.1002/emmm.201000062

Figure 4. Myeloid leukaemia maintenance depends on Stat5.

Figure 4

  1. FACS analysis of BM cells 10 days after a single p(I:C) treatment. Six weeks post-transplantation of Stat5fl/fl or Stat5fl/flMx1Cre bcr/abl+/GFP+ cells, mice received p(I:C) i.p.
  2. Experimental setup for the deletion of Stat5 in myeloid leukaemia.
  3. Kaplan–Meier plot displaying overall survival of p(I:C)-treated and control recipient mice harbouring Stat5fl/flMx1Cre and Stat5fl/fl myeloid leukaemia. One single p(I:C) treatment was performed 6 weeks after transplantation in order to delete Stat5 in leukaemic cells. At the time point of analysis (18 weeks post-injection), 100% (10/10) of Stat5fl/flMx1Cre p(I:C)-treated mice are alive, while recipients from all other groups succumb to leukaemia (n = 8 for Stat5fl/flMx1Cre + PBS, n = 3 for Stat5fl/fl + p(I:C) and n = 3 for Stat5fl/fl + PBS; p < 0.001; mean survival time of 12.5, 11.3 and 12 weeks, respectively).
  4. Immunoblot analysis of Stat5 expression in peripheral blood cells 7 (#1), 8 (#2), 10 (#3) and 12 (#4) weeks after p(I:C) treatment. These censored events are indicated in (C).
  5. Blood smears and histological sections of spleens and BM. Treatment with p(I:C) leads to a massive reduction of WBCs (left panel) and phospho-Stat5 expression (right panels) in Stat5fl/flMx1Cre–bcr/ablp210+ transplanted mice compared to controls (PBS).
  6. Macroscopic anatomy of spleens from Stat5fl/flMx1Cre mice treated with p(I:C) and control mice. A spleen of one age-matched healthy wt mouse is depicted as control.